vs
Side-by-side financial comparison of Hour Loop, Inc (HOUR) and IOVANCE BIOTHERAPEUTICS, INC. (IOVA). Click either name above to swap in a different company.
IOVANCE BIOTHERAPEUTICS, INC. is the larger business by last-quarter revenue ($86.8M vs $56.1M, roughly 1.5× Hour Loop, Inc). On growth, IOVANCE BIOTHERAPEUTICS, INC. posted the faster year-over-year revenue change (17.7% vs 3.0%). Hour Loop, Inc produced more free cash flow last quarter ($3.0M vs $-61.9M). Over the past eight quarters, IOVANCE BIOTHERAPEUTICS, INC.'s revenue compounded faster (1001.6% CAGR vs 50.7%).
Hour Loop, Inc. is an e-commerce retail company that offers a diverse portfolio of products including home goods, apparel, toys, electronics accessories, and daily consumer essentials. It primarily operates through leading third-party online marketplaces, with its core customer base concentrated in North America, focusing on delivering affordable, high-value daily products to mass consumers.
Iovance Biotherapeutics, Inc. is a biopharmaceutical startup based in San Carlos, California. The company works to develop tumor-infiltrating lymphocyte (TIL) therapies against cancer.
HOUR vs IOVA — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $56.1M | $86.8M |
| Net Profit | $-657.3K | — |
| Gross Margin | 49.6% | 67.4% |
| Operating Margin | -1.5% | -84.7% |
| Net Margin | -1.2% | — |
| Revenue YoY | 3.0% | 17.7% |
| Net Profit YoY | 57.0% | — |
| EPS (diluted) | $-0.02 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $56.1M | $86.8M | ||
| Q3 25 | $33.4M | $67.5M | ||
| Q2 25 | $27.1M | $60.0M | ||
| Q1 25 | $25.8M | $49.3M | ||
| Q4 24 | $54.4M | $73.7M | ||
| Q3 24 | $31.1M | $58.6M | ||
| Q2 24 | $28.1M | $31.1M | ||
| Q1 24 | $24.7M | $715.0K |
| Q4 25 | $-657.3K | — | ||
| Q3 25 | $530.6K | $-91.3M | ||
| Q2 25 | $1.2M | $-111.7M | ||
| Q1 25 | $654.5K | $-116.2M | ||
| Q4 24 | $-1.5M | — | ||
| Q3 24 | $469.6K | $-83.5M | ||
| Q2 24 | $649.1K | $-97.1M | ||
| Q1 24 | $1.1M | $-113.0M |
| Q4 25 | 49.6% | 67.4% | ||
| Q3 25 | 51.4% | 43.0% | ||
| Q2 25 | 57.2% | 5.5% | ||
| Q1 25 | 54.7% | -0.8% | ||
| Q4 24 | 45.7% | 68.7% | ||
| Q3 24 | 54.8% | 46.2% | ||
| Q2 24 | 55.7% | -0.8% | ||
| Q1 24 | 58.6% | — |
| Q4 25 | -1.5% | -84.7% | ||
| Q3 25 | 2.2% | -140.7% | ||
| Q2 25 | 6.0% | -189.8% | ||
| Q1 25 | 3.6% | -245.8% | ||
| Q4 24 | -4.5% | -117.5% | ||
| Q3 24 | 2.3% | -152.1% | ||
| Q2 24 | 3.3% | -327.6% | ||
| Q1 24 | 6.2% | -16464.6% |
| Q4 25 | -1.2% | — | ||
| Q3 25 | 1.6% | -135.3% | ||
| Q2 25 | 4.3% | -186.2% | ||
| Q1 25 | 2.5% | -235.5% | ||
| Q4 24 | -2.8% | — | ||
| Q3 24 | 1.5% | -142.7% | ||
| Q2 24 | 2.3% | -312.2% | ||
| Q1 24 | 4.3% | -15800.8% |
| Q4 25 | $-0.02 | — | ||
| Q3 25 | $0.01 | — | ||
| Q2 25 | $0.04 | $-0.33 | ||
| Q1 25 | $0.02 | $-0.36 | ||
| Q4 24 | $-0.04 | $-0.24 | ||
| Q3 24 | $0.01 | $-0.28 | ||
| Q2 24 | $0.02 | $-0.34 | ||
| Q1 24 | $0.03 | $-0.42 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $297.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $7.0M | $698.6M |
| Total Assets | $23.8M | $913.2M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $297.0M | ||
| Q3 25 | — | $300.8M | ||
| Q2 25 | — | $301.2M | ||
| Q1 25 | — | $359.7M | ||
| Q4 24 | — | $323.8M | ||
| Q3 24 | — | $397.5M | ||
| Q2 24 | — | $412.5M | ||
| Q1 24 | $2.9M | $356.2M |
| Q4 25 | $7.0M | $698.6M | ||
| Q3 25 | $7.7M | $702.3M | ||
| Q2 25 | $7.2M | $698.5M | ||
| Q1 25 | $5.8M | $767.9M | ||
| Q4 24 | $5.2M | $710.4M | ||
| Q3 24 | $6.7M | $773.5M | ||
| Q2 24 | $6.2M | $768.5M | ||
| Q1 24 | $5.5M | $680.0M |
| Q4 25 | $23.8M | $913.2M | ||
| Q3 25 | $31.6M | $904.9M | ||
| Q2 25 | $23.0M | $907.4M | ||
| Q1 25 | $19.1M | $966.7M | ||
| Q4 24 | $20.0M | $910.4M | ||
| Q3 24 | $32.4M | $991.1M | ||
| Q2 24 | $20.2M | $964.3M | ||
| Q1 24 | $16.7M | $869.8M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $3.0M | $-52.6M |
| Free Cash FlowOCF − Capex | $3.0M | $-61.9M |
| FCF MarginFCF / Revenue | 5.3% | -71.3% |
| Capex IntensityCapex / Revenue | 0.0% | 10.7% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $2.5M | $-336.2M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $3.0M | $-52.6M | ||
| Q3 25 | $500.4K | $-78.7M | ||
| Q2 25 | $-901.5K | $-67.4M | ||
| Q1 25 | $-23.9K | $-103.7M | ||
| Q4 24 | $1.5M | $-73.3M | ||
| Q3 24 | $-2.2M | $-59.0M | ||
| Q2 24 | $456.2K | $-98.4M | ||
| Q1 24 | $492.9K | $-122.3M |
| Q4 25 | $3.0M | $-61.9M | ||
| Q3 25 | $449.3K | $-89.5M | ||
| Q2 25 | $-901.6K | $-74.9M | ||
| Q1 25 | $-24.6K | $-109.9M | ||
| Q4 24 | $1.5M | $-77.5M | ||
| Q3 24 | $-2.2M | $-61.3M | ||
| Q2 24 | $439.4K | $-98.9M | ||
| Q1 24 | $475.1K | $-126.5M |
| Q4 25 | 5.3% | -71.3% | ||
| Q3 25 | 1.3% | -132.7% | ||
| Q2 25 | -3.3% | -124.9% | ||
| Q1 25 | -0.1% | -222.8% | ||
| Q4 24 | 2.8% | -105.1% | ||
| Q3 24 | -7.0% | -104.6% | ||
| Q2 24 | 1.6% | -317.9% | ||
| Q1 24 | 1.9% | -17685.3% |
| Q4 25 | 0.0% | 10.7% | ||
| Q3 25 | 0.2% | 16.1% | ||
| Q2 25 | 0.0% | 12.4% | ||
| Q1 25 | 0.0% | 12.6% | ||
| Q4 24 | 0.0% | 5.7% | ||
| Q3 24 | 0.0% | 3.9% | ||
| Q2 24 | 0.1% | 1.4% | ||
| Q1 24 | 0.1% | 583.4% |
| Q4 25 | — | — | ||
| Q3 25 | 0.94× | — | ||
| Q2 25 | -0.77× | — | ||
| Q1 25 | -0.04× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | -4.64× | — | ||
| Q2 24 | 0.70× | — | ||
| Q1 24 | 0.46× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
HOUR
Segment breakdown not available.
IOVA
| Amtagvi | $64.9M | 75% |
| Proleukin | $21.9M | 25% |
